Real-World Evidence and Insights

Connect with us at ISPOR

Request a meeting with our RWE experts

ISPOR Exhibit Hall Theater - Live
Unlocking the potential of routine patient health records for RWE
May 15, 1:00 p.m. – 1:30 p.m. EST
Theater 1, Poster & Exhibit Hall

Learning objectives:  

  • Understand the inherent differences between clinical trial and real-world data collection methodologies
  • Address selection bias and ensure the inclusion of the right patients for your RWE study
  • Evaluate the similarity of real-world data to clinical trial data, and the role of analytics in ensuring quality and reliability of study results
  • Review best practices for these RWE challenges to ensure that your data meets regulatory requirements       

Speakers

Bruce Feinberg, DO

VP/Chief Medical Officer, Pharmaceutical and Specialty Solutions

Harlen Hays, MPH

Senior Director, Scientific Operations and Analytics, Real-World Data and Evidence

 

Poster presentations

Wednesday, May 14th

Time Poster title Presenting author
Poster session 1
12:30 – 1:30 p.m.		 Real-World Patient Characteristics and Treatment Patterns in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Patients with Long-Term Survivorship Tammy Schuler, PhD

 

Thursday, May 15th

Time Poster title Presenting author
Poster session 3
12:30 – 1:30 p.m.		 Perspectives on Real-World Management of Stomatitis/Oral Mucositis (S/OM) From Oncologists With Experience Treating Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC) and Metastatic Breast Cancer (mBC)  Client-sponsored and presented 
Poster session 3
12:30 – 1:30 p.m.		 Real World Treatment Patterns, Genetic Testing, and Clinical Outcomes among Patients with mCRPC Treated with Olaparib Monotherapy in US Urology Clinics  Lorraine O’Donnell, PhD
Poster session 4
6:00 - 7:00 p.m.		 Chimeric Antigen Receptor T Cell (CAR T) Therapy as Second-Line (2L) Treatment for Patients With Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Therapy Choice and Treatment Barriers Among US Oncologists Sarah Lucht, PhD

 

Friday, May 16th

Time Poster title Presenting author
Poster session 5
9:00 - 10:00 a.m.		 Provider perspectives on the DREAMM-7 Trial Results and Belantamab Mafodotin (belamaf) in Combination with Bortezomib and Dexamethasone (B-Vd) as a Potential Treatment for Patients with Relapsed or Refractory Multiple Myeloma (R/R MM)”  Sarah Lucht, PhD 

 

 

Real-World Evidence and Insights

Explore our real-world data and evidence solutions